Seamless scale-up: Integrated manufacturing becomes the biopharma standard
From everyday outsourcing to true partnership, an integrated CDMO strategy is redefining how biopharma scales.
Heejeong Kim, EVP and Head of Drug Substance Manufacturing at Samsung Biologics, shares the technical anatomy of a modern biomanufacturing model built on end-to-end integration.
Why this approach matters:
- Streamlined workflows — fewer hand-offs, faster execution
- Standardized operations — consistent quality across global sites
- Scalable infrastructure — readiness that supports first-to-market delivery
From everyday outsourcing to true partnership, an integrated CDMO strategy is redefining how biopharma scales.
Heejeong Kim, EVP and Head of Drug Substance Manufacturing at Samsung Biologics, shares the technical anatomy of a modern biomanufacturing model built on end-to-end integration.
Why this approach matters:
- Streamlined workflows — fewer hand-offs, faster execution
- Standardized operations — consistent quality across global sites
- Scalable infrastructure — readiness that supports first-to-market delivery
Share article
Related Content